

## Abstraction Form

Identifiers			
RefID	First author's last name	Year	Trial name <i>If present/applicable</i>

Population characteristics						
Type of cancer	Stage of disease at diagnosis	Treatment history	Time since active treatment	Baseline age mean (range)	Baseline % female	Baseline % nonwhite
Type of cancer: N (%)	Stage of disease at diagnosis: N (%)	As described	Preferably mean days/weeks/months (SD)	Overall and by group  G1 is always the intervention group; the control group is always the last to be listed		Only report % nonwhite when possible; only give further breakdown if not possible to determine % nonwhite
				Overall: G1: G2:	Overall: G1: G2:	Overall: G1: G2:

<b>Outcomes measured</b>		
<b>Intermediate, health, patient-centered outcomes</b>	<b>Adverse events</b>	<b>Cost and resource utilization</b>
List all intermediate, health, and patient-centered outcomes measured. Describe the length of followup after the intervention ends, e.g., HbA1c (3 months)	List all unintended consequences measured. Describe the length of followup.	List all costs, ER visits, doctor visits, hospitalizations measured. Describe the length of followup.

<b>Comments</b>